
zzso of a suite of zzso for early zzso zzso into distinct zzso and monitoring progression or response to therapy promises significant improvements in clinical outcomes for cancer zzso However, despite the recent progress in zzso technologies based on mass zzso zzso discovery of novel clinical assessment tools has been zzso This is, partly due to the inherent difficulties in working with blood as the zzso for candidate zzso A better understanding of the limitations of blood for comparative protein profiling and a better appreciation of the advantages of cancer tissue or cancer cell zzso have the potential to greatly enhance the zzso 

